Patient Experience


A 28-day user-handling study was conducted to compare Accuhaler®* and the WockAIR® DPI device (marketed at the time of the study as Forspiro®**).¹ Patients (n=24) were all aged 20–86 (mean age 53.8) years and all had been using the Accuhaler® device for at least 1 year prior to the study. They were split into two study groups; users received either limited written instructions (n=12) or fully illustrated instructions (n = 12). During the study the patients took their Accuhaler® as usual, in addition to preparing two mock inhalations from the empty WockAIR® DPI test device each day.

They recorded any observations, difficulties, forgotten doses in a daily diary card. Following the study they rated the test device. All subjects understood the correct sequence of actions for the WockAIR® device and rated all aspects of handling the device as ‘very easy’ or ‘fairly easy’ (except one uninstructed subject who rated ‘ease of determining number of doses left’ as ‘fairly difficult’)

Ratings of ease of use

In addition the Peak Inspiratory Flow Rate (PIFR) through the WockAIR® DPI device was assessed in 10 adult patients with severe COPD. All patients achieved the minimum acceptable flow rate of 30 L/min

Individual PIFRs through the WockAIR® DPI device in 10 adult patients with COPD

Individual PIFRs

Adverse events should be reported. Reporting forms and information can be found at:

Adverse events should also be reported to Wockhardt UK. Please contact us or email us at


1. Virchow JC, Weuthen T, Harmer QJ, Jones S. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opin Drug Deliv. 2014;11(12):1849–57